Gilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by Liberty Wealth Management LLC

Liberty Wealth Management LLC raised its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 990.8% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 2,007 shares of the biopharmaceutical company’s stock after acquiring an additional 1,823 shares during the quarter. Liberty Wealth Management LLC’s holdings in Gilead Sciences were worth $136,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Creative Financial Designs Inc. ADV boosted its stake in shares of Gilead Sciences by 55.9% in the 1st quarter. Creative Financial Designs Inc. ADV now owns 460 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 165 shares during the period. Trustcore Financial Services LLC purchased a new position in shares of Gilead Sciences in the 1st quarter valued at about $34,000. Weaver Consulting Group purchased a new position in shares of Gilead Sciences in the 1st quarter valued at about $34,000. Legacy Advisors LLC purchased a new position in shares of Gilead Sciences in the 2nd quarter valued at about $37,000. Finally, Founders Capital Management boosted its stake in shares of Gilead Sciences by 50.0% in the 1st quarter. Founders Capital Management now owns 600 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 200 shares during the period. 78.87% of the stock is owned by institutional investors.

GILD stock opened at $65.24 on Friday. The stock’s 50 day simple moving average is $66.79. The stock has a market capitalization of $81.44 billion, a PE ratio of 10.61, a price-to-earnings-growth ratio of 3.03 and a beta of 1.16. Gilead Sciences, Inc. has a fifty-two week low of $60.32 and a fifty-two week high of $79.61. The company has a debt-to-equity ratio of 1.13, a quick ratio of 3.75 and a current ratio of 3.76.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $1.82 earnings per share for the quarter, topping the consensus estimate of $1.68 by $0.14. The firm had revenue of $5.69 billion during the quarter, compared to analysts’ expectations of $5.54 billion. Gilead Sciences had a return on equity of 37.12% and a net margin of 26.64%. The firm’s revenue was down 2.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.91 earnings per share. Research analysts predict that Gilead Sciences, Inc. will post 6.65 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 27th. Investors of record on Friday, September 13th will be paid a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 3.86%. The ex-dividend date of this dividend is Thursday, September 12th. Gilead Sciences’s payout ratio is 40.98%.

In other Gilead Sciences news, EVP Brett A. Pletcher sold 7,200 shares of the business’s stock in a transaction that occurred on Tuesday, July 23rd. The stock was sold at an average price of $65.07, for a total value of $468,504.00. Following the completion of the sale, the executive vice president now owns 34,398 shares in the company, valued at $2,238,277.86. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Brett A. Pletcher sold 5,816 shares of the business’s stock in a transaction that occurred on Tuesday, June 18th. The shares were sold at an average price of $68.75, for a total value of $399,850.00. Following the completion of the sale, the executive vice president now owns 27,198 shares of the company’s stock, valued at approximately $1,869,862.50. The disclosure for this sale can be found here. 0.20% of the stock is owned by insiders.

Several brokerages have recently issued reports on GILD. Citigroup set a $78.00 price objective on Gilead Sciences and gave the company a “buy” rating in a research note on Wednesday, July 31st. Cantor Fitzgerald set a $88.00 price objective on Gilead Sciences and gave the company a “buy” rating in a research note on Monday, July 15th. JPMorgan Chase & Co. reiterated a “buy” rating and issued a $85.00 price objective on shares of Gilead Sciences in a research note on Wednesday, July 31st. Maxim Group set a $84.00 price objective on Gilead Sciences and gave the company a “buy” rating in a research note on Wednesday, July 31st. Finally, Zacks Investment Research cut Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Thursday, May 2nd. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, sixteen have given a buy rating and two have issued a strong buy rating to the stock. Gilead Sciences has an average rating of “Buy” and an average price target of $82.29.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Recommended Story: What is a blue-chip stock?

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.